Aims: To assess the safety and efficacy of monotherapy with once-weekly subcutaneous (s.c.) semaglutide vs sitagliptin in Japanese people with type 2 diabetes (T2D).
can achieve glycaemic control and reduce body weight, with a low risk of hypoglycaemia. 5 Semaglutide is a GLP-1 analogue in development for the treatment of T2D, with a 94% homology to native GLP-1. 6 A half-life of 1 week makes it appropriate for once-weekly administration. 6, 7 Sitagliptin, a once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor, is a widely used oral antidiabetic drug (OAD), and the most commonly used DPP-4 inhibitor in Japan. 8 DPP-4 inhibitors achieve glycaemic control by inhibiting DPP-4-dependent inactivation of both GLP-1 and gastric inhibitory polypeptide (GIP), thereby enhancing GLP-1
and GIP receptor signalling, and thus are distinct from GLP-1 RAs, which stably activate GLP-1 receptor signalling. 9 Semaglutide has been evaluated in the "Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes" (SUSTAIN) programme, consisting of six phase III global clinical trials that evaluated the efficacy and safety (including cardiovascular outcomes) of semaglutide vs a range of comparators, including sitagliptin. [10] [11] [12] [13] [14] [15] Two additional phase III clinical trials in the SUSTAIN programme investigated the effect of semaglutide in Japanese populations. 16, 17 In the present trial we evaluated the safety and efficacy of 30 weeks of treatment with once-weekly semaglutide (0.5 and 1.0 mg) vs once-daily sitagliptin (100 mg), both as monotherapy, in
Japanese adults with T2D who were previously stable on diet/exercise or OAD monotherapy. 17 
| MATERIALS AND METHODS

| Trial design
This was a phase III randomized (1:1:1), open-label, parallel-group, active-controlled, single-country (Japan), multicentre trial (NCT02254291; Figure S1 ). This trial was conducted to meet the "Guideline for Clinical Evaluation of Oral Hypoglycaemic Agents"
issued by the Japanese Ministry of Health, Labour and Welfare, 18 which advises that new drugs are assessed as monotherapy to investigate their isolated effects. A specific comparator is not stipulated in the guideline; however, sitagliptin was chosen as an active comparator because it is widely available in Japan, 8 and has a well-known efficacy and safety profile. The trial was conducted in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines 19 and the Declaration of Helsinki. 20 Written informed consent was obtained from all participants.
| Trial population
Japanese men and women were eligible for inclusion if they were aged ≥20 years, diagnosed with T2D, and treated with either diet and exercise therapy in addition to OAD monotherapy if their HbA1c levels were 6.5% to 9.5% (48-80 mmol/mol; hereafter called OAD Table S1 .
| Randomization and masking
Participants were randomly assigned using an interactive voice/web response system in a 1:1:1 ratio to receive once-weekly subcutaneous (s.c.) semaglutide (0.5 or 1.0 mg) or once-daily oral sitagliptin 100 mg. Randomization was stratified according to pre-trial treatment at screening (diet and exercise therapy or OAD monotherapy).
| Drug administration
After an 8-week washout (OAD monotherapy group) or 2-week screening period (diet and exercise only group), participants received s.c. semaglutide 0.5 or 1.0 mg once weekly or sitagliptin 100 mg once daily for 30 weeks, followed by a 5-week follow-up period ( Figure S1 ). Participants in the semaglutide arms followed a fixed dose-escalation regimen of semaglutide 0.5 mg (maintenance dose reached after 4 weeks of 0.25 mg semaglutide once weekly) or semaglutide 1.0 mg (maintenance dose reached after 4 weeks of 0.25 mg semaglutide, followed by 4 weeks of 0.5 mg semaglutide).
In case of a safety concern or unacceptable intolerability, the trial product could be discontinued at the investigator's discretion and was not to be reinitiated. Participants discontinuing trial product prematurely were asked to continue with the scheduled site contact (if necessary, in order to retain the participant in the trial, site visits were replaced by phone contacts after discontinuation) and, as a minimum, were asked to attend the visits for end of treatment and follow-up at the time of the scheduled completion of the trial.
| Trial endpoints and assessments
The primary endpoint was the number of treatment-emergent adverse events (TEAEs) during 30 weeks of treatment. 
| Statistical analysis
Trial sample size was determined based on the "Guideline for Clinical
Evaluation of Oral Hypoglycaemic Agents." 18 With the planned number of randomized participants of 306, a total of 81 participants randomized to each group were expected to complete treatment, assuming a treatment discontinuation rate of 20%. Together with the other trials in the SUSTAIN programme, ≥300 Japanese participants were expected to complete ≥6 months of treatment with semaglutide monotherapy.
Randomized participants receiving at least 1 dose of trial product comprised the full analysis set and the safety analysis set.
A TEAE was defined as an event with onset from first exposure to the follow-up visit scheduled 5 weeks (+1 week visit window) after the last trial product dose.
Main efficacy evaluations were based on assessments collected in the period where participants were treated with trial product, without rescue medication ("on-treatment without rescue medication" period). Supportive analyses of efficacy and safety were based on assessments collected in the period where participants, after randomization, were considered trial participants and where data were to be collected systematically ("in-trial" period). Continuous efficacy endpoints assessed over time were analysed using a mixed model for except for the weight-loss response of ≥10%, which was compared using a Fisher's exact test, as no participants achieved this response in the sitagliptin group.
The sensitivity of the main results of HbA1c and body weight was assessed using complete case analyses (MMRM-based), ANCOVA using the last observation carried forward (LOCF) imputation, and comparator-based multiple imputation.
Data collected throughout the trial, regardless of whether participants discontinued treatment prematurely or initiated rescue medication, were also analysed ("in-trial" analysis; MMRM based); thus, the amount of missing data was expected to be small.
| RESULTS
| Participant disposition and baseline characteristics
In total, 308 adults with T2D were randomized to receive 1 of the 2 semaglutide maintenance doses or sitagliptin, all of whom were Baseline characteristics were generally well balanced between the three groups ( Table 1 ). The majority (76.3%) of participants were men, mean HbA1c was 8.1%, mean diabetes duration was 8.0 years, and the proportion of participants randomized while on pre-trial OAD treatment was 29.9%. Mean body weight was 69.3 kg, although participants in the semaglutide 1.0 mg group were 3.0 kg heavier than in the semaglutide 0.5 mg group (70.8 vs 67.8 kg).
| Primary endpoint
Overall, the proportion of participants reporting TEAEs during the trial (primary endpoint) was higher with semaglutide (0.5 mg: 74.8%;
1.0 mg: 71.6%) than with sitagliptin (66.0%) ( Table 2 ). AEs were mainly mild or moderate in severity ( Table 2 ). The proportion of participants discontinuing treatment because of AEs was relatively low for semaglutide 0.5 mg and sitagliptin (2.9% and 1.9%, respectively), but higher for semaglutide 1.0 mg (10.8%) ( Figure S2 ). Serious AEs (SAEs)
were reported by 5.8%, 2.0% and 1.9% of participants treated with semaglutide 0.5 mg, 1.0 mg and sitagliptin, respectively. Events were distributed among multiple system organ classes, with no clustering (Table S3) . No deaths were reported in the trial ( Table 2 ).
The most frequently reported AEs were gastrointestinal (GI) events; namely constipation (14.6% and 11.8% for semaglutide 0.5 and 1.0 mg, respectively, vs 3.9% with sitagliptin), nausea (10.7%
and 12.7%, vs none with sitagliptin) and diarrhoea (6.8% and 8.8%, vs
1.9% with sitagliptin; Table S4 ). GI events diminished over time ( Figure S3 ). At week 30, the ADA-and JDS-defined target (HbA1c <7.0%) was achieved by 84% and 95% of 0.5 and 1.0 mg semaglutidetreated participants, respectively, vs 35% in the sitagliptin group (both P < .0001). At week 30, the AACE target (HbA1c ≤6.5%) was achieved by 71% and 87% of 0.5 and 1.0 mg semaglutide-treated participants, respectively, vs 16% in the sitagliptin group (both P < .0001; Figure 2C ,D and Table 3 ). Similarly, the proportion of
Flow of participants through the trial. Numbers in brackets within treatment discontinuation category denote subjects who also withdrew from trial, as those who discontinued treatment had the option to continue follow-up. Trial completers were participants who were exposed, did not withdraw from trial and who attended a follow-up participants achieving HbA1c <7.0% with no severe or BG-confirmed symptomatic hypoglycaemia and no weight gain at week 30 was greater with semaglutide than with sitagliptin (72% and 84% vs 18%, respectively; P < .0001 for both; Figure 2E and Table 3 ).
Reductions in mean FPG were significantly greater with semaglutide than with sitagliptin: 2. 
| Body weight
At week 30, body weight (baseline 69.3 kg) was reduced by 2.2 and 3.9 kg with semaglutide 0.5 and 1.0 mg, respectively, vs no reduction with sitagliptin (ETD −2.22 kg, 95% CI −3.02; −1.42, and −3.88 kg, 95% CI −4.70; −3.07; both P < .0001 [ Figure 2F and G and Table 3 A weight loss of ≥5% was achieved by 29% and 57% of 0.5 and 1.0 mg semaglutide-treated participants, respectively, vs 7% in the sitagliptin group (P < .0002 and P < .0001, respectively). A weight loss of ≥10% was achieved by 7% and 19% of 0.5 and 1.0 mg semaglutidetreated participants, respectively, vs 0% in the sitagliptin group (P .0141 and P < .0001, respectively) ( Figure 2H and I, and Table 3 ).
| Other efficacy endpoints
Treatment with semaglutide 0.5 and 1.0 mg reduced BMI and waist circumference, compared with sitagliptin (P < .0001 for both). In addition, decreases in BP were generally greater with semaglutide 1.0 mg than with sitagliptin. The difference in systolic BP with semaglutide 1.0 mg, vs sitagliptin, was significant (ETD −6.01 mmHg, 95% CI −9.16; −2.85; P = .0002); there was no significant difference in diastolic BP (Table 3) .
Total cholesterol and LDL cholesterol were significantly reduced with both semaglutide doses, whereas VLDL cholesterol and triglycerides were significantly reduced with semaglutide 1.0 mg vs sitagliptin.
There was no significant difference in change in HDL cholesterol or FFA levels between semaglutide and sitagliptin ( Figure S6 ).
| Supportive secondary safety endpoints
No severe episodes of hypoglycaemia were reported in any treatment group. One hypoglycaemic episode, classified as "severe or BGconfirmed symptomatic," was reported in the semaglutide 1.0 mg group (Table S5 ). This event was symptomatic and plasma glucose level was 2.6 mmol/L.
No EAC-confirmed pancreatitis events were reported. Mean levels of pancreatic enzymes (lipase and amylase) increased for both semaglutide doses vs sitagliptin. One participant treated with semaglutide 1.0 mg experienced cholelithiasis (Table S5) , which did not lead to premature treatment discontinuation. There were 2 EACconfirmed cardiovascular events in the semaglutide 0.5 mg group ( No malignant neoplasms were reported with semaglutide 0.5 mg (Table S5) . No EAC-confirmed thyroid neoplasms or medullary thyroid carcinomas were reported. Calcitonin levels were similar between groups with no apparent change during the trial. Abbreviations: E, number of events; N, number of participants experiencing at least one event; R, event rate per 100 years of exposure.
TEAEs include events with onset from first exposure to the follow-up visit scheduled 5 weeks (+1 week visit window) after the last trial product dose.
Nervous system disorders were reported by 12 participants (11.7%) in the semaglutide 0.5 mg group, none in the semaglutide 1.0 mg group and 5 (4.9%) in the sitagliptin group (Table S5) , and were composed of single unrelated AEs.
One semaglutide 1.0 mg-treated participant developed antisemaglutide antibodies; however, there was no cross-reaction with endogenous GLP-1. At follow-up, the participant tested antibodynegative and therefore no in vitro neutralizing effect was assessed.
There were 4 reported events of diabetic retinopathy in the semaglutide 0.5 mg group, 2 events in the semaglutide 1.0 mg group, and 4 events in the sitagliptin group.
There were no clinically relevant changes in other safety laboratory assessments, physical examinations or electrocardiograms.
| DISCUSSION
The results of the present trial showed that, in Japanese participants with T2D, more participants receiving semaglutide reported TEAEs than with sitagliptin. This was driven mainly by GI AEs, a well-known side effect of GLP-1 RAs. The discontinuation rate was low and similar between semaglutide 0.5 mg and sitagliptin, but was higher with semaglutide 1.0 mg, owing to a larger proportion of participants experiencing GI AEs. The slightly higher rate of constipation vs nausea and diarrhoea than reported in global trials may have been influenced by other factors, such as differences in diet, cultural differences in how constipation is defined or reported, or AEreporting bias among participants. The frequency of GI AEs FIGURE 2 Efficacy variables. Semaglutide 0.5 mg once weekly and 1.0 mg once weekly, compared with sitagliptin 100 mg once daily: mean HbA1c over time (A); change in mean HbA1c after 30 weeks (B); proportion of participants achieving HbA1c < 7.0% at 30 weeks (C); proportion of participants achieving HbA1c ≤ 6.5% at 30 weeks (D); proportion of participants achieving HbA1c < 7.0% with no severe or BG-confirmed symptomatic hypoglycaemia and no weight gain at week 30 (E); mean body weight over time (F); change in mean body weight after 30 weeks (G); proportion of participants achieving ≥5% (H) or ≥10% (I) weight loss after 30 weeks. *Indicates significance (P < .0001); †indicates significance (P < .05). Values in A, B, F and G are estimated mean (AE standard errors) from a MMRM using "on-treatment without rescue medication" data from subjects in the full analysis set. Dotted line in A and F is the overall mean value at baseline. Values in C, D, H and I are proportions using "on-treatment without rescue medication" data from subjects in the full analysis set. Missing data are imputed from a MMRM and subsequently classified. Abbreviations: BG, confirmed; BG <3.1 mmol/L; MMRM, mixed model for repeated measurements; OR, odds ratio. "Ontreatment without rescue medication" data from participants in the full analysis set, with the exception of pulse rate values, which are observed means using "on-treatment" data from subjects in the safety analysis set. For treatment target endpoints, missing data are imputed from the MMRM and subsequently classified.
diminished over time, as observed with other GLP-1 RAs and other studies with semaglutide. [10] [11] [12] [13] [14] [15] 24, 25 all multinational trials that included Japan, exenatide ER (SUSTAIN 3), 12 and insulin glargine (SUSTAIN 4). 13 The findings also align with trials of liraglutide in participants with T2D, where significant reductions in HbA1c and body weight were observed, either compared with placebo or a thiazolidinedione, all when added to a sulphonylurea 24 ; or compared with placebo or a sulphonylurea, all on a background of metformin. 25 In addition, similar results have been observed with other GLP-1 RAs, such as albiglutide 37 and dulaglutide, 38 either compared with placebo or active comparators such as sitagliptin or insulin glargine, as monotherapy or add-on therapy to other antidiabetic agents.
In the present trial, semaglutide also resulted in marked improvements in cardiometabolic risk compared with sitagliptin, and included reductions in BMI, waist circumference and BP, and improvements in most lipid level profiles. In SUSTAIN 6, semaglutide was associated with a significant 26% reduction in cardiovascular risk (primary composite outcome of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke) compared with placebo in a standard-of-care setting.
whereby the treatment regimens described may not reflect mainstream practice in the T2D population in Japan. Nevertheless, the SUSTAIN programme as a whole covered a broad spectrum of patients with T2D [10] [11] [12] [13] [14] [15] [16] [17] ; for example, SUSTAIN 2, which included patients from Japan, investigated semaglutide vs sitagliptin as an addon to metformin. 11 It should be noted that, in line with regulatory requirements, this trial was designed to assess these treatments as monotherapy, in order to investigate the safety and efficacy of each in isolation. Finally, the collection of body composition data would have been useful, to clarify whether the observed body weight loss with semaglutide was caused by loss of fat or lean body mass. A recently published study involving semaglutide treatment in obese participants has, however, demonstrated that semaglutide is associated with a 3-fold greater loss of fat over lean body mass compared with placebo. 40 Despite these limitations, the significant reductions in HbA1c
and body weight observed in this trial indicate the potential for semaglutide as a treatment option in Japanese participants with T2D. This is important given that many other treatments are either weightneutral or associated with weight gain. [43] [44] [45] In conclusion, in Japanese participants with T2D, more TEAEs were reported with semaglutide (0.5 and 1.0 mg) than with sitagliptin, but semaglutide was well tolerated, with a safety profile similar to that of other GLP-1 RAs. Semaglutide had a greater effect on glycaemic control, body weight reduction and other efficacy variables vs sitagliptin 100 mg monotherapy.
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